Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 26;5(2):504-512.
doi: 10.1182/bloodadvances.2020002439.

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Anjali S Advani  1 , Eric Larsen  2 , Kristina Laumann  3 , Selina M Luger  4 , Michaela Liedtke  5 , Meenakshi Devidas  6 , Zhiguo Chen  7 , Jun Yin  3 , Matthew C Foster  8 , David Claxton  9 , Kristin Coffan  10 , Martin S Tallman  11 , Frederick R Appelbaum  12 , Harry Erba  13 , Richard M Stone  14 , Stephen P Hunger  15 , Jennifer L McNeer  16 , Mignon L Loh  17 , Elizabeth Raetz  18 , Naomi Winick  19 , William Carroll  18 , Richard A Larson  20 , Wendy Stock  20
Affiliations

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Anjali S Advani et al. Blood Adv. .

Abstract

Adolescents and young adults (AYAs) with acute lymphoblastic leukemia have improved outcomes when treated with pediatric-inspired regimens. CALGB 10403 was the largest prospective study to evaluate the feasibility of using a pediatric regimen in AYAs with acute lymphoblastic leukemia up to 40 years of age. This article presents the toxicity events observed in the CALGB 10403 study and compares these toxicities vs those observed among AYAs treated on the same arm of the companion Children's Oncology Group (COG) AALL0232 study. Toxicities in CALGB 10403 were similar to those observed in COG AALL0232. Some grade 3 to 4 adverse events were more often reported in CALGB 10403 compared with COG AALL0232 (hyperglycemia, hyperbilirubinemia, transaminase elevation, and febrile neutropenia). Adverse events correlated with body mass index ≥30 kg/m2 and some with increasing age. The mortality rate in CALGB 10403 was low (4%) and similar to that in the COG AALL0232 trial. A caveat to this analysis is that only 39% of CALGB 10403 patients completed all planned protocol treatment. In COG AALL0232, although 74% of patients aged <18 years completed treatment, only 57% of patients aged ≥18 years completed treatment. This scenario suggests that issues associated with age and treating physician may be a factor. Due to its improved survival rates compared with historical controls, the CALGB 10403 regimen is now a standard of care. The hope is that the rate of protocol completion will increase as more familiarity is gained with this regimen. These trials were registered at www.clinicaltrials.gov as #NCT00558519 (CALGB 10403) and #NCT00075725 (COG AALL0232).

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: D.C. has received research support for clinical studies conducted by the following organizations: Daiichi Sankyo Co. and Astellas Pharma, Incyte Corporation, and Cyclacel Pharmaceuticals, Inc. A.S.A. has received honoraria from Jazz Pharmaceuticals, Sigma Tau, Pfizer, Amgen, Seattle Genetics, and Kite Pharmaceuticals. S.P.H. owns stock in Amgen; and has received consulting fees from Novartis and honoraria from Amgen. R.A.L. has received consulting fees and/or research support for clinical trials to his institution from Amgen, Ariad/Takeda, Cellectis, Celgene, CVS Caremark, Epizyme, Forty Seven, Novartis, and Rafael Pharmaceuticals. M.C.F. reports research funding from Bellicum and Celgene/BMS; research funding and consulting from MacroGenics; and consulting from Agios. R.M.S. reports grant/personal fees from AbbVie, Agios, and Novartis; grants from AROG; and personal fees from Actinium, Argenx, Astellas, AstraZeneca, BioLineRx, Celgene, Daiichi Sankyo, Elevate, Gemoab, Janssen, Jazz, MacroGenics, Otsuka, Pfizer, Hoffmann-La Roche, Stemline, Syndax, Syntrix, Syros, Takeda, and Trovagene. S.M.L. reports honoraria from Daiichi Sankyo, Jazz, Bristol Myers Squibb, Acceleron, and Agios; research funding from Biosight, Celgene, Hoffmann-La Roche, Kura, Onconova, and Ariad. M.L.L. reports advisory board membership for MediSix Therapeutics, Inc. M.S.T. reports research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight, Glycomimetics, Rafael Pharmaceuticals, and Amgen; advisory board membership for AbbVie, BioLineRx, Daiichi Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta-Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight, and Novartis; and royalties from UpToDate. W.S. reports advisory board memberships for Agios, Amgen, Astellas, Kite, Jazz, MorphoSys, and Servier; speaking honoraria from AbbVie and Pfizer; and other from UpToDate and Research to Practice. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Comparison of select adverse events (grade 3-4) during induction (age group 16-21 years). ALT, alanine aminotransferase.
Figure 2.
Figure 2.
Comparison of select adverse events (grade 3-4) during postremission therapy (age group 16-21 years). ALT, alanine aminotransferase; AST, aspartate aminotransferase. *Decreased fibrinogen level.
See this image and copyright information in PMC

References

    1. Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012;87(5):472-478. - PubMed
    1. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. . Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526-534. - PMC - PubMed
    1. Huguet F, Leguay T, Raffoux E, et al. . Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in J Clin Oncol. 2009;27(15):2574]. J Clin Oncol. 2009;27(6):911-918. - PubMed
    1. Larsen EC, Devidas M, Chen S, et al. . Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-2388. - PMC - PubMed
    1. Stock W, Luger SM, Advani AS, et al. . A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559. - PMC - PubMed

Publication types

Associated data